PMID- 20827188
OWN - NLM
STAT- MEDLINE
DCOM- 20110222
LR  - 20101015
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 17
IP  - 6
DP  - 2010 Nov
TI  - Unrelated stem cell transplantation for patients with multiple myeloma.
PG  - 538-43
LID - 10.1097/MOH.0b013e32833e5b01 [doi]
AB  - PURPOSE OF REVIEW: The role of allogeneic stem cell transplantation (SCT) in 
      treatment of myeloma patients is still controversial. Meanwhile, the numbers of 
      unrelated SCT for hematological diseases in Europe are higher than for human 
      leukocyte antigen (HLA)-identical sibling transplantations, but in multiple 
      myeloma only 39% of the allogeneic transplantations are performed from unrelated 
      donors and only a minority were done within prospective clinical trials. RECENT 
      FINDINGS: The few published data of unrelated SCT in multiple myeloma reported a 
      higher treatment-related mortality for standard myeloablative conditioning in 
      comparison to reduced-intensity conditioning. Despite the heterogeneous patient 
      selection in the trial, lower nonrelapse mortality and improved survival can be 
      achieved by careful donor selection (10/10 HLA-alleles, male donor). Natural 
      killer-alloreactivity might play a role, but conclusive data are lacking. 
      Transplantation in more advanced or refractory patients is associated with an 
      inferior outcome. The results of an unrelated SCT seem to be comparable to those 
      of HLA-identical siblings, but a direct comparison is lacking so far. SUMMARY: 
      Unrelated SCT in multiple myeloma is feasible, but prospective clinical trials 
      using unrelated stem cell donors are urgently needed to define the role of an 
      unrelated SCT in multiple myeloma in the era of novel agents.
FAU - Kroger, Nicolaus
AU  - Kroger N
AD  - Clinic for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, 
      Hamburg, Germany. nkroeger@uke.uni-hamburg.de
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
SB  - IM
MH  - Humans
MH  - Multiple Myeloma/*surgery
MH  - Stem Cell Transplantation/*methods
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
EDAT- 2010/09/10 06:00
MHDA- 2011/02/23 06:00
CRDT- 2010/09/10 06:00
PHST- 2010/09/10 06:00 [entrez]
PHST- 2010/09/10 06:00 [pubmed]
PHST- 2011/02/23 06:00 [medline]
AID - 10.1097/MOH.0b013e32833e5b01 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2010 Nov;17(6):538-43. doi: 10.1097/MOH.0b013e32833e5b01.